User login
Key data on chronic conditions in type 2 diabetes, presented at the 2022 European Association for the Study of Diabetes (EASD), are discussed by Dr Carol Wysham, from the University of Washington School of Medicine.
Focusing on nonalcoholic fatty liver disease (NAFLD), Dr Wysham reports on a large national registry out of Sweden that explored the rates of microvascular complications in patients with NAFLD. The study showed that NAFLD is independently associated with chronic kidney disease and retinopathy. Coupling the findings with the rise in diabetes risk per population, the presence of NAFLD may represent an additional risk factor for microvascular complications.
Next, Dr Wysham comments on another large, real-world study using data from the UK National Health Service (NHS), investigating a scoring system for noninvasive fibrosis, which the study concludes is a promising prognostic biomarker of liver and cardiovascular events in adults with type 2 diabetes.
She then turns to a clinical study that evaluated whether the 2018 EASD/ADA routine treatment recommendation algorithm is associated with decreasing cardiovascular events and death in type 2 diabetes. The study found that nonadherence to the recommendations was associated with an increase in major adverse cardiovascular events and mortality.
--
Carol Wysham, MD, Clinical Professor of Medicine, Department of Medicine, University of Washington School of Medicine; Clinical Endocrinologist, Rockwood Center for Diabetes and Endocrinology, MultiCare Health Systems, Spokane, Washington
Carol Wysham, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Endocrine Society; MultiCare Health Systems
Received research grant from: Allergan; Abbott; Corcept; Eli Lilly; Mylan; Novo Nordisk; Regeneron
Key data on chronic conditions in type 2 diabetes, presented at the 2022 European Association for the Study of Diabetes (EASD), are discussed by Dr Carol Wysham, from the University of Washington School of Medicine.
Focusing on nonalcoholic fatty liver disease (NAFLD), Dr Wysham reports on a large national registry out of Sweden that explored the rates of microvascular complications in patients with NAFLD. The study showed that NAFLD is independently associated with chronic kidney disease and retinopathy. Coupling the findings with the rise in diabetes risk per population, the presence of NAFLD may represent an additional risk factor for microvascular complications.
Next, Dr Wysham comments on another large, real-world study using data from the UK National Health Service (NHS), investigating a scoring system for noninvasive fibrosis, which the study concludes is a promising prognostic biomarker of liver and cardiovascular events in adults with type 2 diabetes.
She then turns to a clinical study that evaluated whether the 2018 EASD/ADA routine treatment recommendation algorithm is associated with decreasing cardiovascular events and death in type 2 diabetes. The study found that nonadherence to the recommendations was associated with an increase in major adverse cardiovascular events and mortality.
--
Carol Wysham, MD, Clinical Professor of Medicine, Department of Medicine, University of Washington School of Medicine; Clinical Endocrinologist, Rockwood Center for Diabetes and Endocrinology, MultiCare Health Systems, Spokane, Washington
Carol Wysham, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Endocrine Society; MultiCare Health Systems
Received research grant from: Allergan; Abbott; Corcept; Eli Lilly; Mylan; Novo Nordisk; Regeneron
Key data on chronic conditions in type 2 diabetes, presented at the 2022 European Association for the Study of Diabetes (EASD), are discussed by Dr Carol Wysham, from the University of Washington School of Medicine.
Focusing on nonalcoholic fatty liver disease (NAFLD), Dr Wysham reports on a large national registry out of Sweden that explored the rates of microvascular complications in patients with NAFLD. The study showed that NAFLD is independently associated with chronic kidney disease and retinopathy. Coupling the findings with the rise in diabetes risk per population, the presence of NAFLD may represent an additional risk factor for microvascular complications.
Next, Dr Wysham comments on another large, real-world study using data from the UK National Health Service (NHS), investigating a scoring system for noninvasive fibrosis, which the study concludes is a promising prognostic biomarker of liver and cardiovascular events in adults with type 2 diabetes.
She then turns to a clinical study that evaluated whether the 2018 EASD/ADA routine treatment recommendation algorithm is associated with decreasing cardiovascular events and death in type 2 diabetes. The study found that nonadherence to the recommendations was associated with an increase in major adverse cardiovascular events and mortality.
--
Carol Wysham, MD, Clinical Professor of Medicine, Department of Medicine, University of Washington School of Medicine; Clinical Endocrinologist, Rockwood Center for Diabetes and Endocrinology, MultiCare Health Systems, Spokane, Washington
Carol Wysham, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Endocrine Society; MultiCare Health Systems
Received research grant from: Allergan; Abbott; Corcept; Eli Lilly; Mylan; Novo Nordisk; Regeneron
